Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 220

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 220
---

serving as a director or officer of Enfusion, is or was serving at the request of Enfusion as a director, officer, employee, agent, trustee or fiduciary of any of Enfusion’s subsidiaries or another Person, in each case, at or before the
Effective Time to the fullest extent permitted under applicable law and to the extent such Indemnified Party is entitled to indemnification from Enfusion on the date of the Merger Agreement pursuant to the organizational documents of Enfusion or any
indemnification agreement in effect as of the date of the Merger Agreement and (2) fulfill and honor in all respects the obligations of Enfusion pursuant to each indemnification agreement between Enfusion and any Indemnified Party set forth in
the Enfusion Disclosure Schedules and any indemnification provision (including advancement of expenses) and any exculpation provision set forth in the certificate of incorporation or by-laws of
Enfusion, in each case, as in effect on the date of the Merger Agreement; provided that all rights to indemnification, exculpation and advancement of expenses in respect of any claim asserted or made within such period will continue until the
final disposition of such claim.

During the period commencing at the Effective Time and ending on the sixth anniversary of the Effective
Time, the Surviving Corporation will (and Clearwater will cause the Surviving Corporation to) cause the organizational documents of the Surviving Corporation to contain provisions with respect to indemnification, exculpation and the advancement of
expenses that are at least as favorable to those subject to those provisions as the indemnification, exculpation and advancement of expenses provisions set forth in the organizational documents of Enfusion as of the date of the Merger Agreement.

139

In addition, if the Surviving Corporation or any of its successors or assigns (1) consolidates with or merges into any other person and will not be the continuing or surviving corporation or entity of such consolidation or merger or (2) transfers or conveys all or substantially all of its properties and assets to any person, then the successors and assigns of the Surviving Corporation will assume the above obligations. For more information, please refer to the section of this Proxy Statement/Prospectus titled “The Transactions—Interests of Enfusion’s Directors and Executive Officers in the Transactions.” Conditions to the Transactions The obligation of each of the Buyer Parties and Enfusion to consummate the Transactions is subject to the satisfaction or waiver (where permissible pursuant to applicable law